HEPA Hepion Pharmaceuticals, Inc. Stock Quote

HEPA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.54	Insider Own	0.10%	Shs Outstand	76.23M	Perf Week	-7.04%
Market Cap	139.51M	Forward P/E	-	EPS next Y	-0.51	Insider Trans	143.88%	Shs Float	62.62M	Perf Month	-11.48%
Income	-20.40M	PEG	-	EPS next Q	-0.20	Inst Own	12.60%	Short Float	3.05%	Perf Quarter	-11.06%
Sales	-	P/S	-	EPS this Y	65.60%	Inst Trans	-	Short Ratio	0.30	Perf Half Y	-39.94%
Book/sh	2.31	P/B	0.80	EPS next Y	70.40%	ROA	-70.00%	Target Price	-	Perf Year	15.62%
Cash/sh	0.54	P/C	3.43	EPS next 5Y	-	ROE	-97.40%	52W Range	1.26 - 4.83	Perf YTD	-15.53%
Dividend	-	P/FCF	-	EPS past 5Y	64.10%	ROI	-	52W High	-62.94%	Beta	1.14
Dividend %	-	Quick Ratio	9.10	Sales past 5Y	-	Gross Margin	-	52W Low	42.06%	ATR	0.15
Employees	13	Current Ratio	9.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.50	Volatility	4.40% 7.95%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	52.40%	Profit Margin	-	Rel Volume	0.56	Prev Close	1.85
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	6.31M	Price	1.79
Recom	2.00	SMA20	-10.57%	SMA50	-16.55%	SMA200	-35.41%	Volume	982,385	Change	-3.24%

Jul-20-20

Resumed

ROTH Capital

Buy

$14

Mar-23-21 07:15AM	DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceuticals Lead Drug, CRV431 GlobeNewswire
Mar-22-21 04:30PM	Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference GlobeNewswire
Mar-11-21 07:30AM	Hepion Pharmaceuticals to Present on CRV431 and AI-POWR at NASH-TAG 2021 ACCESSWIRE +11.48%
Feb-18-21 04:30PM	Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering ACCESSWIRE
Feb-16-21 06:45AM	Hepion Pharmaceuticals Announces Pricing of Public Offering GlobeNewswire -25.25%
Feb-12-21 04:45PM	Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock ACCESSWIRE
Feb-10-21 07:30AM	Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer ACCESSWIRE
Feb-09-21 04:30PM	Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference ACCESSWIRE
Feb-05-21 02:00AM	Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director GlobeNewswire
Jan-29-21 03:07PM	Penny Stocks to Buy Using Technical Analysis for February 2021 Investopedia
Jan-05-21 08:00AM	Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences ACCESSWIRE
Dec-29-20 04:15PM	Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH ACCESSWIRE
07:30AM	Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH ACCESSWIRE
Dec-22-20 07:30AM	Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19 ACCESSWIRE
Dec-10-20 08:55AM	Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH ACCESSWIRE +9.04%
Dec-02-20 07:30AM	Hepion Pharmaceuticals CRV431 Demonstrates Additional Potential Advantage in Liver Disease ACCESSWIRE
Nov-30-20 05:30PM	Hepion Announces Closing of Public Offering of Common Stock ACCESSWIRE
Nov-24-20 07:20PM	Hepion Pharmaceuticals Prices Public Offering ACCESSWIRE -7.84%
Nov-18-20 07:30AM	Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation of Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH ACCESSWIRE
Nov-17-20 04:30PM	Hepion Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Healthcare Symposium ACCESSWIRE
Nov-12-20 08:30AM	Hepion Pharmaceuticals to Present at The Liver Meeting Digital Experience(TM) 2020 ACCESSWIRE
Nov-10-20 09:00AM	Hepion Pharmaceuticals Completes First Cohort Enrollment in Phase 2a 'AMBITION' Clinical Trial ACCESSWIRE
Nov-05-20 08:57AM	Is Hepion Pharmaceuticals (NASDAQ:HEPA) In A Good Position To Invest In Growth? Simply Wall St.
Oct-27-20 07:45AM	Hepion Pharmaceuticals to Present on Therapeutic Approaches to COVID-19 and NASH at Two Virtual Conferences on October 28 and 29, 2020 ACCESSWIRE
Oct-05-20 07:30AM	Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development & Announces Creation of Clinical Pharmacology Analytics Team ACCESSWIRE
Sep-29-20 08:30AM	Hepion Pharmaceuticals to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference ACCESSWIRE
Sep-17-20 08:00AM	Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases ACCESSWIRE +5.88%
Sep-01-20 07:30AM	Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431 ACCESSWIRE -5.74%
Aug-27-20 07:15AM	Hepion Pharmaceuticals to Present CRV431 Preclinical Data at the 2020 Digital International Liver Congress(TM) ACCESSWIRE
Aug-12-20 07:15AM	Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431's Antiviral Properties ACCESSWIRE
Aug-05-20 07:15AM	Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 'AMBITION' Clinical Trial ACCESSWIRE +12.78%
Jul-07-20 07:30AM	Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431 ACCESSWIRE +43.06%
Jun-29-20 04:15PM	Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431 ACCESSWIRE +5.45%
Jun-22-20 04:15PM	Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Kidney Fibrosis ACCESSWIRE
Jun-10-20 04:15PM	Hepion Pharmaceuticals Welcomes Industry Veteran and Drug Development Expert, Dr. Peter Wijngaard, to its Board of Directors ACCESSWIRE
May-20-20 04:15PM	Hepion Pharmaceuticals Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431 ACCESSWIRE
May-19-20 07:00AM	Hepion Pharmaceuticals' CRV431 the First Cyclophilin Inhibitor to Advance to Phase 2 Trial for NASH Fibrosis ACCESSWIRE +9.47%
Mar-12-20 08:15AM	Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study ACCESSWIRE -24.40%
Feb-19-20 04:30PM	Anti-Fibrotic Activity of Hepion Pharmaceuticals CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases ACCESSWIRE
Feb-12-20 04:15PM	Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431 ACCESSWIRE
Jan-28-20 04:15PM	Hepions NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study ACCESSWIRE +5.73%
Jan-08-20 04:15PM	Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference ACCESSWIRE
Jan-06-20 04:15PM	Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs ACCESSWIRE
Dec-23-19 11:17AM	Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII Zacks +6.75%
Dec-12-19 11:42AM	Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF Zacks
Dec-11-19 09:08AM	Buy These 5 Stocks as New Analysts Initiate Coverage Zacks
Dec-10-19 04:20PM	Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431 ACCESSWIRE
Dec-09-19 04:15PM	Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019 ACCESSWIRE +8.09%
Dec-03-19 04:15PM	Hepion Pharmaceuticals Announces Canadian Research Teams Academic Appointments ACCESSWIRE
08:30AM	Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference ACCESSWIRE
Nov-21-19 09:01AM	Hepion Rips Higher After NASH Drug Confirms Antifibrotic Activity In Animal Study Benzinga +38.37%
08:04AM	Hepion Pharmaceuticals' stock rockets after upbeat results of preclinical study of liver cirrhosis treatment MarketWatch
Nov-20-19 04:15PM	Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease ACCESSWIRE
Nov-07-19 04:15PM	Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019 ACCESSWIRE
08:30AM	Hepion Pharmaceuticals' CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH ACCESSWIRE
Oct-23-19 04:15PM	Hepion Pharmaceuticals to Present on CRV431 at the 3rd Annual NASH Summit ACCESSWIRE
Oct-16-19 04:15PM	Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431's Potential as a Treatment for Chronic Liver Diseases ACCESSWIRE
Oct-10-19 08:00AM	World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director ACCESSWIRE
Oct-03-19 04:15PM	Hepion Pharmaceuticals Strengthens Management Team with Three Key Promotions ACCESSWIRE
Sep-04-19 08:30AM	Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference GlobeNewswire
Sep-03-19 04:30PM	Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements GlobeNewswire
Aug-14-19 08:30AM	Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431 GlobeNewswire
Aug-07-19 01:00PM	Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board GlobeNewswire
Jul-31-19 09:20AM	Hepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceutical Sciences at University of Alberta GlobeNewswire

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cavan John T	Chief Financial Officer	Feb 18	Buy	2.00	10,000	20,000	14,800	Feb 18 04:05 PM
Foster Robert T	CEO and Director	Feb 18	Buy	2.00	20,000	40,000	45,259	Feb 18 04:05 PM
Wijngaard Peter	Director	Feb 16	Buy	2.20	10,000	22,000	30,000	Feb 18 04:06 PM
Wijngaard Peter	Director	Dec 18	Buy	1.91	20,000	38,200	20,000	Dec 21 09:17 AM
Foster Robert T	CEO and Director	Dec 08	Buy	1.58	25,000	39,418	25,259	Dec 08 01:56 PM
BRANCACCIO JOHN P	Director	Dec 02	Buy	1.53	7,000	10,710	7,008	Dec 02 06:05 PM
JACOB GARY S	Director	Dec 01	Buy	1.66	12,000	19,920	12,059	Dec 01 07:53 PM
Cavan John T	Chief Financial Officer	Nov 25	Buy	1.62	4,500	7,290	4,800	Nov 30 04:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience